You are viewing the site in preview mode

Skip to main content
Fig. 4 | BMC Endocrine Disorders

Fig. 4

From: Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)

Fig. 4

Patients achieving hormonal control at the end-of-study/early withdrawal visit. Data are from the intention-to-treat population. Decisions regarding the titration of treatment were made based on GH and IGF-1 levels measured at Week 13. CI, confidence interval; GH, growth hormone; IGF-1, insulin-like growth factor-1; PR, prolonged release; RD, risk difference

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us